Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of petosemtamab with docetaxel or pembrolizumab in metastatic non-small cell lung cancer
MOH_2026-03-29_015743Phase 2Completed
- Sponsor
- Merus
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of petosemtamab in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma (4 cohorts), sponsored by Merus. Started Mar 2026; status: completed.
02
Drugs
petosemtamab
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on MOH_2026-03-29_015743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-29_015743.